ESC Premium Access

Role of serum biomarkers for monitoring disease progression in the cardio-specific alpha-galactosidase A genotype N215S

Congress Presentation

About the speaker

Doctor Daniel Oder

University Hospital Würzburg, Würzburg (Germany)
0 follower

6 more presentations in this session

Comprehensive cardiovascular magnetic resonance assessment of anderson-fabry cardiomyopathy- natural history and assessment of treatment effect

Speaker: Doctor A. Reid (Manchester, GB)

Thumbnail

Treatment of Fabry disease with a new oral drug: Initial real-world single-center experience

Speaker: Mr J. Muentze (Wuerzburg, DE)

Thumbnail

Prompt initiation of agalsidase alfa therapy is associated with improved cardiovascular outcomes in the Fabry Outcome Survey

Speaker: Professor A. Linhart (Prague, CZ)

Thumbnail

Efficacy of enzyme replacement therapy in Fabry disease with advanced organ involvement

Speaker: Doctor P. Nordbeck (Wuerzburg, DE)

Thumbnail

Long-term benefit of enzyme replacement therapy on cardiac manifestation in Japanese Fabry disease

Speaker: Doctor I. Anan (Tokyo, JP)

Thumbnail

Access the full session

Cardiomyopathy in Fabry disease

Speakers: Doctor D. Oder, Doctor A. Reid, Mr J. Muentze, Professor A. Linhart, Doctor P. Nordbeck...
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb